AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On September 30, 2025, , ranking 17th in total trading activity across U.S. equities. , reflecting mixed investor sentiment amid earnings season dynamics.
Recent market commentary highlighted shifting subscriber growth patterns and content pipeline updates as key drivers for near-term volatility. Analysts noted that management's guidance on international expansion timelines and streaming technology investments remained pivotal for positioning the stock in a competitive streaming landscape.
Technical indicators showed increased short-term pressure as the 50-day moving average dipped below critical support levels. Trading activity was concentrated in extended-hours sessions, with institutional investors adjusting exposure ahead of Q3 earnings reports. Market participants are closely monitoring content production budgets and user retention metrics for directional clues.
To run a daily-rebalanced "top-500-by-volume" strategy we need to clarify a few practical points: 1. Universe scope • Is it all U.S. listed common stocks (NYSE + NASDAQ)? • ADRs/ETFs excluded? 2. Weighting / portfolio construction • Equal-weight each of the 500 names, or volume-weighted, or market-cap-weighted? • Rebalance fully every trading day (i.e., sell all yesterday’s holdings and buy today’s list)? 3. Transaction assumptions • Round-trip trading cost / slippage to apply (if any). 4. Tool limitation note The current back-test engine available here evaluates one ticker (index, ETF, or stock) at a time. Running a true cross-sectional portfolio of 500 tickers is therefore not directly supported via a single call. Typical work-arounds are: • Use a composite vehicle that already aggregates a large-cap/high-liquidity basket (e.g., SPY or RSP) as a proxy, or • Narrow the scope to a single security of interest.

Hunt down the stocks with explosive trading volume.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet